NIH signs on IDT Biologika to manufacture clinical trial supply

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Lucshen)
(Image: Getty/Lucshen)
The NIH has contracted IDT Biologika to manufacture five E. coli master cell banks for BLA, IND, and Phase I/II trial supply.

IDT BIologika, a global vaccine and biopharmaceutical contract development and manufacturing organization (CDMO), has been awarded a task order from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to manufacture five E. coli master ell banks.

Germany-based IDT Biologika will manufacture the five master cell banks at its Rockville, Maryland facility, which its CEO Jürgen Betzing said is well-positioned to meet the requirements.

The Maryland facility was opened in 2015​ and is equipped to handle process development, cell banking, current good manufacturing practice (cGMP) manufacturing, purification, and fill and finish services. IDT Biologika Corporation, a subsidiary of IDT Biologika, acquired the site from Aeras​.

This contract is within the 10-year Indefinite Delivery, Indefinite Quantity (IDIQ) agreement with the NIAID. The 2018 agreement supports early research and development projects and provides manufacturing of Phase I/II clinical material for the use in Investigational New Drug (IND) applications and Biologic License Applications (BLA).

Vaccine development grants

The Coalition for Epidemic Preparedness Innovations​ (CEPI) also recently collaborated with IDT Biologika, granting the CRO $36m in 2018 to develop a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

In 2016, IDT Biologika was also contracted by the Biomedical Advanced Research and Development Authority (BARDA) to provide live virus filling and finishing services​ at its Maryland facility.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars